Parexel launches dedicated biotech division

By Melissa Fassbender

- Last updated on GMT

(Image: Getty/Pattanaphong Khuankaew)
(Image: Getty/Pattanaphong Khuankaew)

Related tags Parexel Parexel Biotech

Parexel Biotech will support emerging companies from development through commercialization with tailored services and customized guidance, says division lead.

The division – Parexel Biotech – offers a new biotech-focused team and organizational structure for customers, and will be led by James Anthony, global head of biotech, and Graciela Racaro, global head of biotech operations.

“Parexel understands that emerging biotech companies have different needs and require a different style of service than large, established pharmaceutical companies, and will be able to provide these companies with tailored, customized guidance to meet those specific needs,”​ Anthony told Outsourcing-Pharma.

The contract research organization (CRO) has worked with biotech companies for several years, but the new division now provides a dedicated team focused on the needs of emerging companies, he added.

“Emerging biotech customers serve as the innovative arm of the industry, driving new therapies forward for development with the ultimate goal of market approval,” ​said Anthony – and the CRO's percentage of its overall business sponsored by this market segment has grown significantly over the past decade.

Parexel Biotech’s offering will include regulatory and strategic consulting, the ability to recruit patients and conduct trials, generation of real-world evidence (RWE) leveraging internal expertise and partnerships, such as with Datavant and SHYFT Analytics, among others.

Related news

Show more

Related products

show more

Drug Solubility and the Need for Speed

Drug Solubility and the Need for Speed

Lonza Small Molecules | 28-Mar-2023 | Technical / White Paper

A growing number of new chemical entities are highly insoluble, leading to problems with bioavailability. Drug manufacturers therefore have to find ways...

Are You Prepared to Meet the New FDA Guidelines?

Are You Prepared to Meet the New FDA Guidelines?

Elligo Health Research® | 23-Mar-2023 | Insight Guide

On April 15, 2022, the U.S. Food and Drug Administration issued a new draft guidance to clinical research sponsors on creating a plan to enroll more participants...

ODM and CDASH in CRF design

ODM and CDASH in CRF design

Formedix | 10-Mar-2023 | Technical / White Paper

The lesser-known Operational Data Model (ODM) standard is often overlooked as it's not required by any regulators. So, why should you be interested...

4 Warning Signs Your Research Site Is in Trouble

4 Warning Signs Your Research Site Is in Trouble

Elligo Health Research® | 10-Mar-2023 | Insight Guide

You want your clinical research practice to be a success for your business and your patients, but how can you tell if it’s in trouble? Read this article...

Related suppliers

Follow us

Products

View more

Webinars